Compare · AZN vs YMAB
AZN vs YMAB
Side-by-side comparison of AstraZeneca PLC (AZN) and Y-mAbs Therapeutics Inc. (YMAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and YMAB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN carries a market cap of $286.03B.
- AZN has hit the wire 22 times in the past 4 weeks while YMAB has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 20 for YMAB).
- Company
- AstraZeneca PLC
- Y-mAbs Therapeutics Inc.
- Price
- $185.18+0.39%
- -
- Market cap
- $286.03B
- -
- 1M return
- +10.68%
- -
- 1Y return
- +106.42%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2018
- News (4w)
- 22
- 0
- Recent ratings
- 25
- 20
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
- FDA Approval for KLYGEFA issued to ALEXION PHARM
- AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- SEC Form 6-K filed by AstraZeneca PLC
Latest YMAB
- SEC Form 15-12G filed by Y-mAbs Therapeutics Inc.
- Director Hamill Laura returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Wg Biotech Aps closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by SVP, Danyelza Bus. Unit Head Gentilcore Douglas J
- Director Gill David N returned $50,095 worth of shares to the company (30,905 units at $1.62), closing all direct ownership in the company (SEC Form 4)
- Director Tyagi Ashu returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)
- CHIEF BUSINESS OFFICER Gad Thomas returned 60,235 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP, CFO and Treasurer Pfreundschuh Peter P. returned 77,800 shares to the company, closing all direct ownership in the company (SEC Form 4)
- PRESIDENT & CEO Rossi Michael J returned 129,101 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SVP & CHIEF OPERATING OFFICER Wilms Joris returned 39,301 shares to the company, closing all direct ownership in the company (SEC Form 4)